Breaking News

The outsider who's upended Eli Lilly’s cancer pipeline

March 25, 2026
Jacob Van Naarden is president of Lilly Oncology and head of business development for the drug giant.
James Salzano/Eli Lilly

STAT+ | How an outsider crept into Eli Lilly's top ranks — and plans to drive its business forward 

Lilly acquired both drug rights and top talent in the $8 billion deal. Here's an inside look at how Loxo's Jacob Van Naarden rose to power inside Eli Lilly.

By Matthew Herper


STAT+ | Bhattacharya addresses CDC director role, works to bolster staff morale in first all-hands meeting

Acting CDC Director Bhattacharya faced tough staff questions on job cuts and attack fallout. Announcement about a new director is expected by Thursday.

By Helen Branswell


California considers seal of approval for foods that are not ultra-processed

California bill would label foods as not ultra-processed, even as scientists debate definitions and courts weigh legality of similar laws.

By Sarah Todd



Adobe

Opinion: Emergency departments are not equipped to help patients with dementia

Relatively minor changes to the process of getting care in emergency departments would substantially improve the experience of patients with dementia.

By Gabriela Khazanov


Heart failure is common. A quick MRI could improve diagnosis and guide treatment

A new MRI method measures cardiac oxygen use in three minutes without catheters or radiation, offering a simpler way to study heart failure and metabolism.

By Elizabeth Cooney


STAT+ | Sarepta Therapeutics shares rise on early promise for rare disease drugs

New results from small studies in a pair of treatments for rare, muscle-wasting diseases could support the beleaguered company's pivot.

By Damian Garde


Smoke rises after a U.S.-Israeli military strike in Tehran, Iran, on March 3, 2026.
Vahid Salemi/AP

Opinion: The U.S. needs to be worried about Iranian biological materials

Congress should demand a full accounting of what we know about Iran's biological weapons, and fast.

By Ashish K. Jha


STAT+ | FDA approves Denali Therapeutics drug for Hunter syndrome

The decision is notable in part because it follows a string of FDA rejections or calls for additional data on rare disease drugs.

By Andrew Joseph and Jason Mast


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Daily Recap? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2026, All Rights Reserved.

No comments